{"product_id":"docs-vrio-analysis","title":"Doximity, Inc. (DOCS): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlocking the secrets to Doximity, Inc. (DOCS)'s market dominance starts here: this VRIO analysis distills whether its core assets truly offer a sustainable competitive advantage by examining their Value, Rarity, Inimitability, and Organization. Don't just guess at their success - click below to see the sharp, strategic breakdown that reveals exactly what makes Doximity, Inc. (DOCS) powerful and where they might be vulnerable.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eDoximity, Inc. (DOCS) - VRIO Analysis: 1. Vast, Verified Physician Network Penetration\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at the core asset of Doximity, Inc. (DOCS), and honestly, it’s the bedrock of their entire valuation. This isn't just a big list of emails; it's the most concentrated, verified audience of U.S. medical professionals available anywhere. As of the end of their fiscal year 2025 on March 31, 2025, this network included more than \u003cstrong\u003e80%\u003c\/strong\u003e of all U.S. physicians.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue: Unparalleled Access for Customers\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis density is what makes the platform so valuable to your customers - think pharmaceutical companies or health systems needing to market, recruit, or engage doctors. They are paying for guaranteed reach to the decision-makers. For context, Doximity generated \u003cstrong\u003e$570.4 million\u003c\/strong\u003e in revenue in fiscal year 2025, with subscription revenue alone hitting \u003cstrong\u003e$543.8 million\u003c\/strong\u003e, largely driven by the value derived from this captive audience.\u003c\/p\u003e\n\u003cp\u003eIt’s the difference between shouting into a crowded stadium and speaking directly to the team huddle. That level of verified access is what you’re paying for.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity: A Moat Built Over a Decade\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAchieving this level of penetration across every specialty - from neurosurgery to family medicine - is incredibly rare in the fragmented U.S. healthcare landscape. Competitors can’t just buy a list; they have to earn the trust of every single physician to get them to verify their credentials and actively use the platform. This sheer scale across specialties is a massive moat in this sector.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability: The Trust and Time Barrier\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eImitating this is high-difficulty. It’s not just about the technology; it’s about the network effect. Every new doctor joins because the existing doctors are there, and vice-versa. Competitors face significant hurdles because building equivalent trust and achieving that verification standard takes years of consistent, reliable service. You can’t just copy the code; you have to copy the decade of professional goodwill.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization: Business Model Alignment\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDoximity’s entire operational structure is built to exploit this network density. Their entire business model, from how they structure their subscription sales to how they develop new AI workflow tools, is designed around monetizing the high-value interactions this network enables. They are definitely organized to extract maximum value from this core asset.\u003c\/p\u003e\n\n\u003cp\u003eHere is a quick summary of how this core resource scores:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eCompetitive Implication\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue (V)\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eCompetitive Parity to Advantage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity (R)\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInimitability (I)\u003c\/td\u003e\n\u003ctd\u003eCostly to Imitate\u003c\/td\u003e\n\u003ctd\u003eTemporary to Sustained Advantage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization (O)\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eSustained Competitive Advantage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eTo give you a clearer picture of the scale and operational success tied to this network as of the close of fiscal 2025:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNetwork penetration: More than \u003cstrong\u003e80%\u003c\/strong\u003e of U.S. physicians.\u003c\/li\u003e\n\u003cli\u003eFY 2025 Total Revenue: \u003cstrong\u003e$570.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFY 2025 Subscription Revenue: \u003cstrong\u003e$543.8 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFY 2025 Free Cash Flow Growth: \u003cstrong\u003e50%\u003c\/strong\u003e year-over-year.\u003c\/li\u003e\n\u003cli\u003eGross Margin (Recent): \u003cstrong\u003e90.2%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFinance: draft the Q3 2026 subscription revenue forecast sensitivity analysis by next Wednesday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eDoximity, Inc. (DOCS) - VRIO Analysis: 2. High Customer Revenue Retention\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: Signals that existing customers find the platform indispensable, leading to predictable, high-quality recurring revenue streams. Net Revenue Retention (NRR) was an astounding \u003cstrong\u003e118%\u003c\/strong\u003e on a trailing 12-month basis for Fiscal Q2 2026.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: An NRR above 100% is excellent; \u003cstrong\u003e118%\u003c\/strong\u003e is top-tier for B2B SaaS, showing existing clients spend significantly more each year. For comparison, the NRR was \u003cstrong\u003e117%\u003c\/strong\u003e on a trailing twelve-month basis at the end of Fiscal Q3 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: Moderate. While competitors can offer similar features, replicating the deep integration that drives this retention takes time.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: Sales and product teams are clearly focused on upselling and expanding within the existing, high-value customer base. The shift to longer-term, bundled campaigns contributes to this stability.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Temporary to Sustained.\u003c\/p\u003e\n\u003cp\u003eThe deepening integration is evidenced by the growth in the high-value customer segment and the increasing mix of recurring, multi-module programs:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003cth\u003ePeriod\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Revenue Retention (NRR)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e118%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTrailing 12-Months (Q2 FY2026)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNRR (Top 20 Customers)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e122%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTrailing 12-Months (Q3 FY2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCustomers with $\\ge$ $500,000 TTM Subscription Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e121\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ2 FY2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYear-over-Year Growth in $\\ge$ $500,000 Cohort\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e16%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ2 FY2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue from $\\ge$ $500,000 Cohort\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e84%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ2 FY2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntegrated Program Bookings Mix\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eOver 40%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ2 FY2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntegrated Program Bookings Mix (Prior Year)\u003c\/td\u003e\n\u003ctd\u003eLess than \u003cstrong\u003e5%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eQ2 FY2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe focus on embedding workflow and AI tools directly into daily routines is driving this expansion revenue:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eQuarterly active prescribers using workflow tools reached an all-time high of over \u003cstrong\u003e650,000\u003c\/strong\u003e in Q2 FY2026.\u003c\/li\u003e\n\u003cli\u003eAI tool suite users (Scribe and DoxGPT) increased over \u003cstrong\u003e50%\u003c\/strong\u003e sequentially in Q2 FY2026.\u003c\/li\u003e\n\u003cli\u003eIntegrated, AI-optimised multi-module programs represented over \u003cstrong\u003e40%\u003c\/strong\u003e of Q2 bookings in FY2026, up from under \u003cstrong\u003e5%\u003c\/strong\u003e a year prior.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eDoximity, Inc. (DOCS) - VRIO Analysis: 3. Proprietary AI\/Workflow Tool Integration\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Directly addresses physician burnout by offering tools like Doximity GPT to summarize lengthy patient files, saving precious clinical time. Doximity GPT was shown to save a user 15 minutes of admin time when drafting a referral letter. The Doximity AI Scribe is offered free of charge to verified U.S. physicians, nurse practitioners, physician assistants, and medical students. Comparable AI scribe services can cost hundreds of dollars per month per user.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. While many are developing AI, Doximity’s tools are integrated directly into the workflow of the largest physician network, which is unique. The Doximity network includes more than 80% of U.S. physicians across all specialties and practice areas.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Temporary. The core AI tech can be copied, but the integration into the existing, trusted platform is harder to match quickly. Usage of Doximity's built-in AI features nearly tripled compared to the prior quarter (as of Q2 FY2026). AI tools, in general, grew more than 5x year-on-year (as of Q1 FY2026).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Management has shifted focus to clinical AI products, showing commitment to this growth vector. Integrated, AI-optimised multi-module programs represented over 40% of Q2 bookings, a significant increase from under 5% a year ago.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary.\u003c\/p\u003e\n\u003cp\u003eKey metrics demonstrating the impact and scale of AI\/Workflow integration:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric Category\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eWorkflow Tool User Base (Q2 FY2026)\u003c\/td\u003e\n\u003ctd\u003eRecord number of prescribers using workflow tools\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e650,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAI Tool Growth (YoY)\u003c\/td\u003e\n\u003ctd\u003eGrowth rate for all AI tools (as of Q1 FY2026)\u003c\/td\u003e\n\u003ctd\u003eMore than \u003cstrong\u003e5x\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAI Feature Adoption (QoQ)\u003c\/td\u003e\n\u003ctd\u003eUsage increase for built-in AI features (as of Q2 FY2026)\u003c\/td\u003e\n\u003ctd\u003eNearly \u003cstrong\u003etripled\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAI Scribe Stickiness\u003c\/td\u003e\n\u003ctd\u003eWeekly retention rate for AI Scribe\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e75%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue Program Mix\u003c\/td\u003e\n\u003ctd\u003ePercentage of Q2 bookings from AI-optimised multi-module programs\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e40%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eSpecific impacts of AI and Workflow Tools:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe Doximity network includes more than 80% of U.S. physicians.\u003c\/li\u003e\n\u003cli\u003eAI Scribe and DoxGPT users grew over 50% from the prior quarter (Q2 FY2026).\u003c\/li\u003e\n\u003cli\u003eThe AI-first strategy supports a Net Revenue Retention Rate (NRR) of 118% on a trailing 12-month basis (as of Q1 FY2026).\u003c\/li\u003e\n\u003cli\u003eThe company's Adjusted EBITDA margin for Q2 FY2026 was 60%.\u003c\/li\u003e\n\u003cli\u003eThe AI Scribe is offered at no cost to users, contrasting with comparable services costing hundreds of dollars per month.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eDoximity, Inc. (DOCS) - VRIO Analysis: 4. Exceptional Gross Profit Margins\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Indicates highly efficient service delivery and strong pricing power, allowing for significant reinvestment or high profitability. Gross profit margins hover around \u003cstrong\u003e90.2%\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThe high margin demonstrates the inherent scalability and low marginal cost structure of the digital platform business model when applied to a large, engaged user base.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDoximity Gross Margin (Recent Reported)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e90.2%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDoximity Non-GAAP Gross Margin (Q3 FY2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e93%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDoximity Gross Margin (Q1 FY2026)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e89.2%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIndustry Average Gross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e47.4%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Very rare for a tech platform, especially one dealing with complex data and compliance. The margin significantly exceeds the industry average.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNon-GAAP gross margin in the third quarter of fiscal 2024 was \u003cstrong\u003e93%\u003c\/strong\u003e versus \u003cstrong\u003e91%\u003c\/strong\u003e in the prior year period.\u003c\/li\u003e\n\u003cli\u003eGross Profit for the three months ended in September 2025 was \u003cstrong\u003e$152.1 Mil\u003c\/strong\u003e on Revenue of \u003cstrong\u003e$168.5 Mil\u003c\/strong\u003e, resulting in a Gross Margin % of \u003cstrong\u003e90.25%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eGross margin contracted to \u003cstrong\u003e89.2%\u003c\/strong\u003e in the fiscal first quarter of 2026.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. Achieving this margin requires massive scale and low marginal cost per user, which Doximity has achieved. Replicating the network effect and established compliance framework is difficult.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The company is structured to scale its software offerings with minimal variable cost increases. This structure supports margin maintenance and profitability, evidenced by strong bottom-line performance.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAdjusted EBITDA margin reached \u003cstrong\u003e54%\u003c\/strong\u003e in Q3 fiscal 2024.\u003c\/li\u003e\n\u003cli\u003eAdjusted EBITDA for Q3 fiscal 2024 was \u003cstrong\u003e$73.3 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company raised its fiscal 2024 annual EBITDA guidance midpoint to \u003cstrong\u003e$225 million\u003c\/strong\u003e or a \u003cstrong\u003e47%\u003c\/strong\u003e margin.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. The high margin acts as a significant barrier to entry, allowing for aggressive reinvestment or superior profitability compared to lower-margin competitors.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eDoximity, Inc. (DOCS) - VRIO Analysis: 5. Strong Enterprise Customer Cohort Concentration\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e A small group of top clients drives the majority of revenue, suggesting deep, strategic relationships rather than fragmented, small-scale sales. Customers spending over $\\$500\\text{k}$ annually accounted for \u003cstrong\u003e84%\u003c\/strong\u003e of total revenue in Q3 2025. This high concentration is driven by the stickiness of the platform for large pharmaceutical companies measuring marketing effectiveness.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. High concentration is common, but having such a large percentage from a relatively small, high-spending cohort is notable. The number of customers contributing at least $\\$500,000$ in subscription-based revenue on a trailing twelve-month basis was \u003cstrong\u003e114\u003c\/strong\u003e in Q3 2025, representing a \u003cstrong\u003e21%\u003c\/strong\u003e increase from the prior year.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. Competitors can target these large health systems and pharmaceutical firms, but Doximity has the established relationship and proven return on investment metrics.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Sales efforts are effectively concentrated on securing and expanding these large, lucrative contracts. The company's Net Revenue Retention (NRR) rate was \u003cstrong\u003e117%\u003c\/strong\u003e on a trailing twelve-month basis in Q3 2025, indicating existing customers are increasing their spend. The top 20 customers showed even stronger growth, with an NRR of \u003cstrong\u003e122%\u003c\/strong\u003e in Q3 2025.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary to Sustained. The high NRR suggests a sustained advantage derived from deep integration, while the concentration itself presents a risk if a few key clients reduce spend.\u003c\/p\u003e\n\n\u003cp\u003eSupporting Financial and Statistical Data:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eIn Q2 Fiscal 2026, the cohort of customers spending at least $\\$500,000$ annually grew to \u003cstrong\u003e121\u003c\/strong\u003e, still representing \u003cstrong\u003e84%\u003c\/strong\u003e of total revenues.\u003c\/li\u003e\n\u003cli\u003eThe top 20 customers demonstrated an even higher Net Revenue Retention rate of \u003cstrong\u003e124%\u003c\/strong\u003e in Q2 FY2025.\u003c\/li\u003e\n\u003cli\u003eThe company's overall subscription revenue in FY2025 was $\\$543.8$ million, growing at a \u003cstrong\u003e21%\u003c\/strong\u003e year-over-year clip.\u003c\/li\u003e\n\u003cli\u003eDoximity serves over \u003cstrong\u003e250\u003c\/strong\u003e health systems and hospital clients in delivering telehealth care.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003ePeriod\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCustomers $\u0026gt;\\$500\\text{k}$ ACV\u003c\/td\u003e\n\u003ctd\u003eQ3 FY2025\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e114\u003c\/strong\u003e Customers\u003c\/td\u003e\n\u003ctd\u003eRepresented \u003cstrong\u003e84%\u003c\/strong\u003e of total revenue.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCustomers $\u0026gt;\\$500\\text{k}$ ACV\u003c\/td\u003e\n\u003ctd\u003eQ2 FY2026\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e121\u003c\/strong\u003e Customers\u003c\/td\u003e\n\u003ctd\u003eRepresented \u003cstrong\u003e84%\u003c\/strong\u003e of revenues.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYoY Growth in $\u0026gt;\\$500\\text{k}$ Cohort\u003c\/td\u003e\n\u003ctd\u003eQ3 FY2025\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e21%\u003c\/strong\u003e Increase\u003c\/td\u003e\n\u003ctd\u003eFrom 94 customers in the prior year.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYoY Growth in $\u0026gt;\\$500\\text{k}$ Cohort\u003c\/td\u003e\n\u003ctd\u003eQ2 FY2026\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e16%\u003c\/strong\u003e Growth\u003c\/td\u003e\n\u003ctd\u003eAdded 17 customers in the cohort year-over-year.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop 20 Customer NRR (TTM)\u003c\/td\u003e\n\u003ctd\u003eQ3 FY2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e122%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIndicates strong expansion within the largest clients.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOverall NRR (TTM)\u003c\/td\u003e\n\u003ctd\u003eQ3 FY2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e117%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIndicates overall customer spending growth.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eDoximity, Inc. (DOCS) - VRIO Analysis: 6. Brand Trust and Physician-Centric Ethos\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e This is the intangible trust that gets physicians to use the platform for sensitive communications and career decisions. Their mission is to help every physician be more productive.\u003c\/p\u003e\n\u003cp\u003eThe platform demonstrates utility through:\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eUnique active users on a quarterly, monthly, weekly and daily basis were all up double-digit percentages year on year (Q3 FY2024).\u003c\/li\u003e\n\u003cli\u003eOver 580,000 unique providers using workflow tools last quarter (Q4 FY2024).\u003c\/li\u003e\n\u003cli\u003eDoximity Personas boosted engagement by 44% in a case study.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e In medicine, trust is the ultimate currency, and Doximity has successfully positioned itself as physician-first.\u003c\/p\u003e\n\u003cp\u003eNetwork penetration statistics support this positioning:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eContext Year\/Period\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNetwork Penetration (Claimed)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\u0026gt;80%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCurrent Claim\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhysicians Reporting Overworked\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e85%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMay\/June 2025 Poll\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWilling to Trade Pay for Work-Life Balance\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e77%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMay\/June 2025 Poll\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGender Pay Gap\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e26%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024 Data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Trust is built over a decade of consistent, non-exploitative service, which cannot be bought.\u003c\/p\u003e\n\u003cp\u003eHistorical growth illustrates time-based establishment:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e10% of all U.S. doctors listed as members by 2013.\u003c\/li\u003e\n\u003cli\u003e40% of all U.S. doctors listed as members by 2014.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The company culture and product design prioritize physician utility over short-term monetization grabs, which helps maintain this trust.\u003c\/p\u003e\n\u003cp\u003eFinancial performance metrics reflect high operational efficiency:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial Metric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003ePeriod\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFiscal Year 2024 Total Revenues\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$475.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFY2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFiscal Year 2024 Revenue Growth YoY\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e13%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFY2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ4 Adjusted EBITDA Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e47.8%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ4 FY2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Income Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e31.0%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFY2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eDoximity, Inc. (DOCS) - VRIO Analysis: 7. Robust Balance Sheet and Cash Position\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides financial flexibility for strategic acquisitions, weathering economic downturns, and funding aggressive R\u0026amp;D without immediate external pressure.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eCash, cash equivalents, and marketable securities totaled approximately \u003cstrong\u003e$805.6 million\u003c\/strong\u003e as of September 30, 2024.\u003c\/li\u003e\n\u003cli\u003eCash and cash equivalents and marketable securities totaled \u003cstrong\u003e$756.23 million\u003c\/strong\u003e on the balance sheet as of September 30, 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High. Many growth-focused tech firms carry debt; Doximity has a clean balance sheet with no debt.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eFY2025 (Ended Mar 31, 2025)\u003c\/th\u003e\n\u003cth\u003ePrior Period (FY2024)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Debt\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDebt to Equity Ratio\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. This is a result of past operational success and prudent financial management, not an easily copied asset.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Management has clearly prioritized strong cash flow generation to build this war chest.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eFiscal year 2025 Free Cash Flow (FCF) was \u003cstrong\u003e$266.7 million\u003c\/strong\u003e, a \u003cstrong\u003e49.61%\u003c\/strong\u003e increase from 2024.\u003c\/li\u003e\n\u003cli\u003eFiscal year 2025 Operating Cash Flow was \u003cstrong\u003e$273.3 million\u003c\/strong\u003e, up \u003cstrong\u003e48%\u003c\/strong\u003e year-over-year.\u003c\/li\u003e\n\u003cli\u003eQ4 FY2025 Free Cash Flow reached \u003cstrong\u003e$97.0 million\u003c\/strong\u003e, up \u003cstrong\u003e56%\u003c\/strong\u003e year-over-year.\u003c\/li\u003e\n\u003cli\u003eQ3 FY2025 Free Cash Flow reached \u003cstrong\u003e$91.6 million\u003c\/strong\u003e, up about \u003cstrong\u003e37%\u003c\/strong\u003e year-over-year.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial Metric (FY2025)\u003c\/th\u003e\n\u003cth\u003eAmount (USD Millions)\u003c\/th\u003e\n\u003cth\u003eYear-over-Year Growth\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$570.4\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e20%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Income\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$223.2\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e51.2%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFree Cash Flow\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$266.7\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e50%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eDoximity, Inc. (DOCS) - VRIO Analysis: 8. Data Assets from Physician Surveys\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eProprietary, large-scale data sets, like the 2025 Physician Compensation Report derived from over \u003cstrong\u003e37,000\u003c\/strong\u003e surveys completed between January and December \u003cstrong\u003e2024\u003c\/strong\u003e, offer unique market intelligence to clients and establish Doximity as a thought leader. This data is definitely valuable.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eData Asset Metric\u003c\/td\u003e\n\u003ctd\u003eReported Number\u003c\/td\u003e\n\u003ctd\u003eData Period\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 Report Survey Respondents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e37,000+\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSurveys completed in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCumulative Survey Responses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e230,000+\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOver the last six years\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVerified U.S. Physician Membership\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\u0026gt;80%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCurrent Network Size\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eHigh. No other single entity has access to such a broad, verified sample of U.S. physicians for compensation and sentiment data.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eHigh. The data is historical and requires years of network growth to compile. Cumulative data spans over \u003cstrong\u003e230,000\u003c\/strong\u003e responses over \u003cstrong\u003esix years\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eThey actively use this data generation as a value-add for their marketing and research solutions customers. The company reported total revenue of \u003cstrong\u003e$570.4 million\u003c\/strong\u003e for fiscal year 2025.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eData informs specific market insights, such as the 2024 average physician pay increase of \u003cstrong\u003e3.7%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eData highlights significant pay disparities, including a gender pay gap of \u003cstrong\u003e26%\u003c\/strong\u003e in 2024.\u003c\/li\u003e\n\u003cli\u003eData is leveraged to support solutions like Clinical Trial Recruitment and Engagement services.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eSustained.\u003c\/p\u003e\n\n\n\u003cbr\u003e\u003ch2\u003eDoximity, Inc. (DOCS) - VRIO Analysis: 9. Strategic Customer Base (Pharma\/Health Systems)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e These customers represent the highest-value advertisers and recruiters, and their continued spending validates the platform’s utility for professional engagement. Pharma clients are actively requesting AI optimization for their programs.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eValue Metrics\u003c\/h\u003e\u003c\/h\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\/Data Point\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2025 Total Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$570.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2025 Subscription Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$543.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop 20 Customer Growth (FY2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e23%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCustomers Contributing $\\ge$ $500k Revenue (Q2 FY2025 TTM)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e103\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedian ROI for Pharma Clients (Historical\/Mentioned)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e10:1\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe 103 customers contributing at least $500,000 in subscription-based revenue on a trailing twelve-month basis as of Q2 FY2025 accounted for 83% of total revenue.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eModerate. Other platforms serve these groups, but Doximity’s unique access makes it a strategic necessity for them.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eModerate. Competitors can sell to these groups, but Doximity has the established, measurable ROI channel.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe Client Portal provides these customers with direct ROI tracking, locking them into the ecosystem.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eOrganization Adoption Data\u003c\/h\u003e\u003c\/h\u003e\n\u003cul\u003e\n\u003cli\u003eThe rollout of Doximity's client portal was open to more than 40% of Pharma brand clients in Q2 FY2025.\u003c\/li\u003e\n\u003cli\u003eSales for new Point-of-Care and Formulary products were each up more than 100% year-over-year in Q3 FY2025.\u003c\/li\u003e\n\u003cli\u003eQuarterly active prescribers using specialty-specific AI tools jumped more than 50% quarter-over-quarter (as of Q2 FY2026).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eTemporary to Sustained.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eFinance\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe midpoint of the updated Fiscal Year 2026 revenue guidance is set at \u003cstrong\u003e$643 million\u003c\/strong\u003e (range: $640 million to $646 million).\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516151914645,"sku":"docs-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/docs-vrio-analysis.png?v=1740167802","url":"https:\/\/dcf-model.com\/fr\/products\/docs-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}